Pfizer suffers setback in ENBREL battle
Pfizer suffered a setback last week in its Australian battle to protect ENBREL (etanercept), when its preliminary discovery application against Sandoz was dismissed by Justice Burley in the Federal...
Pfizer suffered a setback last week in its Australian battle to protect ENBREL (etanercept), when its preliminary discovery application...
Read More
Key changes to Indonesian patent and trademark laws
Indonesia officially enacted Law No. 11 of year 2020, commonly known as the Omnibus Law, on 2 November 2020. The Omnibus Law contains revisions to multiple laws, including patent...
Indonesia officially enacted Law No. 11 of year 2020, commonly known as the Omnibus Law, on 2 November 2020....
Read More
Extension of time for grace period in Australia
A 12 month “grace period” is provided in Australian Patent law, which allows any information made publicly available, with or without the consent of the applicant, the patentee, or...
A 12 month “grace period” is provided in Australian Patent law, which allows any information made publicly available, with...
Read More
IP-led recovery: putting COVID-19 in the rear-view mirror
There has been a steady decline in innovation in Australia since the Global Financial Crisis (GFC) in 2007. This is clear from the Australian Patent Office data which shows...
There has been a steady decline in innovation in Australia since the Global Financial Crisis (GFC) in 2007. This...
Read More
Revised Patent Rules in India effective from 19 October, 2020
The India Ministry of Commerce and Industry has issued a notification that the Patents (Amendment) Rules, 2020, was released and enforced on 19 October, 2020. In summary, the key amendments...
The India Ministry of Commerce and Industry has issued a notification that the Patents (Amendment) Rules, 2020, was released...
Read More
Australian Patent Office considers the plausibility of Swiss-style claims
Gliknik, Inc. v CSL Behring Lengnau AG  APO 46 (“Gliknik”) concerned a patent application for engineered proteins intended for use as replacements for intravenous immunoglobulin.  The application included claims...
Gliknik, Inc. v CSL Behring Lengnau AG  APO 46 (“Gliknik”) concerned a patent application for engineered proteins intended for...
Read More
What is an intermediate generalisation anyway?
The Australian provisions outlining whether an amendment to a patent specification is allowable or not were revised with the IP Laws Amendment (Raising the Bar) Act 2012 which came...
The Australian provisions outlining whether an amendment to a patent specification is allowable or not were revised with the...
Read More